Join to View Full Profile
2000 Circle of Hope DrSalt Lake City, UT 84112
Phone+1 801-587-4745
Fax+1 801-662-4707
Dr. Maese is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Utah HealthFellowship, Pediatric Hematology/Oncology, 2012 - 2015
UPMC Medical EducationResidency, Pediatrics, 2009 - 2012
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2009
Certifications & Licensure
AZ State License 2021 - 2027
CO State License 2021 - 2027
MT State License 2021 - 2026
UT State License 2012 - 2026
ID State License 2021 - 2025
NV State License 2021 - 2025
WY State License 2021 - 2025
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
- Join now to see all
Clinical Trials
- Intervention For AYAS With Cancer Risk Syndromes Start of enrollment: 2021 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.Maria Isabel Achatz, Anita Villani, Alison A Bertuch, Gaëlle Bougeard, Vivian Y Chang
Clinical Cancer Research. 2025-03-12 - Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome.Conrad J Fernandes, Yun K Du, Ann Naumer, Laura A Kagami, Anh Le
Pancreas. 2025-02-27 - Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study.Luke Maese, Mignon L Loh, Mi Rim Choi, Shirali Agarwal, Etsuko Aoki
Blood Advances. 2025-01-14
Press Mentions
- Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual MeetingJune 7th, 2022
- Asparaginase Erwinia Chrysanthemi (Recombinant)-RywnJune 29th, 2021
Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaJanuary 4th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
